Belessi Chrysoula J, Parasi Aikaterini S, Manioudaki Helen S, Laoutaris Nikolaos P, Legakis Nikolaos C, Peros Georgios Th, Androulakis Georgios A
Department of Hematology, General State Hospital of Nikea, Piraeus, Greece.
J Surg Oncol. 2003 Apr;82(4):247-55. doi: 10.1002/jso.10227.
DNA ploidy, S-phase fraction (SPF), and proliferating cell nuclear antigen (PCNA) are considered to be significant prognostic factors in non-Hodgkin lymphomas. However, reports on their prognostic importance in gastric lymphoma patients are relatively lacking.
In the present study, we retrospectively studied the above-mentioned parameters in 29 patients with primary gastric lymphoma; 11/29 had B-low grade mucosa associated lymphoid tissue lymphoma (B-MALT), while 18/29 had diffuse large B-cell lymphoma (DLBCL), according to WHO classification. Proliferative activity was studied by staining against PCNA; in addition, the prognostic significance of DNA ploidy and SPF, as determined by flow cytometry, were investigated and compared to the results of the PCNA stainings.
Seven out of 29 patients were found to have aneuploid tumors; DNA index values were >1 for all aneuploid lymphomas. There was no difference in DNA aneuploidy in MALT vs. DLBCL. The mean percentage of SPF was 11.4. SPF was found significantly lower in MALT vs. DLBCL (P < 0.05). The mean percentage of PCNA positive tumor cells was 52.6. PCNA protein expression was significantly lower in MALT vs. DLBCL (P < 0.0001). There was a significant positive correlation between PCNA score and SPF (P < 0.01, by Spearman analysis). DNA ploidy had no impact on survival in the present study. Both SPF and PCNA expression were important prognostic factors in the univariate analysis; however, in the multivariate analysis, the only independent prognostic factor for survival was PCNA expression.
These findings indicate that SPF and PCNA are significant prognostic factors in patients with primary gastric lymphomas. However, in the present study, DNA ploidy had no impact on survival in patients with primary gastric lymphomas.
DNA倍体、S期分数(SPF)和增殖细胞核抗原(PCNA)被认为是非霍奇金淋巴瘤重要的预后因素。然而,关于它们在胃淋巴瘤患者中的预后重要性的报道相对较少。
在本研究中,我们回顾性研究了29例原发性胃淋巴瘤患者的上述参数;根据世界卫生组织分类,29例中有11例为B低级别黏膜相关淋巴组织淋巴瘤(B-MALT),18例为弥漫性大B细胞淋巴瘤(DLBCL)。通过PCNA染色研究增殖活性;此外,研究了通过流式细胞术测定的DNA倍体和SPF的预后意义,并与PCNA染色结果进行比较。
29例患者中有7例发现非整倍体肿瘤;所有非整倍体淋巴瘤的DNA指数值均>1。MALT与DLBCL的DNA非整倍体情况无差异。SPF的平均百分比为11.4。发现MALT中的SPF显著低于DLBCL(P<0.05)。PCNA阳性肿瘤细胞的平均百分比为52.6。MALT中PCNA蛋白表达显著低于DLBCL(P<0.0001)。PCNA评分与SPF之间存在显著正相关(Spearman分析,P<0.01)。在本研究中,DNA倍体对生存无影响。在单因素分析中,SPF和PCNA表达均为重要的预后因素;然而,在多因素分析中,生存的唯一独立预后因素是PCNA表达。
这些发现表明,SPF和PCNA是原发性胃淋巴瘤患者重要的预后因素。然而,在本研究中,DNA倍体对原发性胃淋巴瘤患者的生存无影响。